Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bivatuzumab mertansine, bivatuzumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 41 Parkinson's papers of 23,091 | 0.51 |
| pathways Reactome | 10 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 2872
Sealed predictions
- CD44 in dopamine neurons, braak+0.51 (p 0.160) → +0.41 (p 0.273)receipt 2880
Swarm cases
receipt 2880: CD44 in dopamine neurons, braak
- power
- full sample +0.44 (p 0.070, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.42 (p 0.086, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.44 (p 0.066, n 18). could be the mix.
- skeptic
- leave-one-out range +0.35 to +0.57, sign flips 0; without severely affected donors +0.44 (p 0.070, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD44 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts